Sacubitril + Valsartan is a combination drug that is used in the treatment of heart failure.
Sacubitril is a prodrug of sacubitrilat (LBQ-657). Its effect includes the inhibition of neprilysin, which is a neutral endopeptidase (NEP). This further increases the secretion of endogenous vasoactive peptides including natriuretic peptides, bradykinin and adrenomedullin.
Valsartan, on the other hand, is an angiotensin II type 1 (AT1) receptor blocker. It antagonizes AT1-induced vasoconstriction, aldosterone, catecholamine and arginine vasopressin release, water consumption, and hypertrophic response.